Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)

NCT00046059 | Completed

• 2 other identifiers: 00005800-HG-0058
• Study Type: observational
• Target: 3,481
• Locations: 1 country
• Sites: 2

Brief Summary

Attention Deficit Hyperactivity Disorder (ADHD) is the most common behavioral disorder in childhood, affecting 3-5% of children between the ages of 7 and 17. Family studies suggest that there is a genetic component to ADHD. Scientists believe that it is a complex disorder in which two or more genes may be involved. Potentially eligible families will be asked to give written consent to participate and will be asked to complete questionnaires for each member in the family. In addition, an interview will be administered to the parent of minors enrolled in the study to determine their eligibility for being in the study. This screening tool is computerized and will take approximately 45 minutes to administer per child. Once screenings are completed, a blood collection kit will be sent to the family to take to their local medical care provider, have blood samples drawn and sent to NIH. There is no cost to the family to participate. We would like to enroll entire families, with both parents and all children.

Conditions

ADHD

Keywords

Linkage; Gene Identification; Hyperactivity; Natural History; Attention Deficit Hyperactivity Disorder; ADHD

Outcome Measures

Primary Outcomes (1)

• ADHD

  The main objective of the study is to conduct genetic and behavioral studies that will closely characterize the genetic influences in diagnosis, prognosis, severity, and pharmacological response in ADHD patients.

  Ongoing

Study Arms (1)

ADHD

Children aged 7-17 with ADHD and their families.

Eligibility Criteria

• Age: 7 Years - 110 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

1\. Families with children, seven through 17 years of age, diagnosed with ADHD (defined as the proband for the study). 2. The probands siblings, either affected with ADHD (concordant) or unaffected (discordant), seven years of age and above, including adult siblings. 3. The parents, both mothers and fathers, of enrolled probands.

You may qualify if:

• This study will enroll families with the following characteristics:
• Families with children, seven through 17 years of age, diagnosed with ADHD (defined as the proband for the study).
• The probands siblings, either affected with ADHD (concordant) or unaffected (discordant), seven years of age and above, including adult siblings.
• The parents, both mothers and fathers, of enrolled probands.
• The study will enroll both male and female probands of any ethnic background and race. The prevalence of ADHD is higher in males than in females, so we would expect to have a higher number of male probands than female probands. Both male and female siblings and male and female parents of probands will be enrolled.
• Adults who are or may be unable to provide informed consent will be excluded.
• Probands with one parent affected with ADHD or with neither parent affected with ADHD are eligible. Probands from bilineal families, families with both parents affected with ADHD, will be excluded for statistical reasons.
• \. Ability to read and understand spoken English, since the questionnaires, scales, and interviews that we have license to use in this study are in English.

You may not qualify if:

• Some conditions can confound the diagnosis of ADHD. Probands with the following conditions will be excluded from enrollment or will be withdrawn from the study if the condition is discovered subsequent to enrollment:
• Prematurity
• Neurological conditions
• Cardiac surgery
• Prenatal drug exposure
• Hydrocephaly
• Mental Retardation (IQ\<80)
• Known genetic syndromes
• Known CNS disorders
• Known lead toxicity
• Tourette Disorder
• Obsessive-Compulsive Disorder
• Major Depression on both proband and affected sibling
• Pervasive Developmental Disorder
• Age under 7 years old

Sponsors & Collaborators

• National Human Genome Research Institute (NHGRI): lead

Study Sites (2)

University of California, Irvine Medical Center

Orange, California, 92668, United States

Location

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

• Anderson JC, Williams S, McGee R, Silva PA. DSM-III disorders in preadolescent children. Prevalence in a large sample from the general population. Arch Gen Psychiatry. 1987 Jan;44(1):69-76. doi: 10.1001/archpsyc.1987.01800130081010.

  PMID: 2432848 BACKGROUND

• Biederman J, Faraone S, Milberger S, Guite J, Mick E, Chen L, Mennin D, Marrs A, Ouellette C, Moore P, Spencer T, Norman D, Wilens T, Kraus I, Perrin J. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry. 1996 May;53(5):437-46. doi: 10.1001/archpsyc.1996.01830050073012.

  PMID: 8624187 BACKGROUND

• Faraone SV, Biederman J, Chen WJ, Milberger S, Warburton R, Tsuang MT. Genetic heterogeneity in attention-deficit hyperactivity disorder (ADHD): gender, psychiatric comorbidity, and maternal ADHD. J Abnorm Psychol. 1995 May;104(2):334-345. doi: 10.1037/0021-843X.104.2.334.

  PMID: 7790635 BACKGROUND

Related Links

• NIH Clinical Center Detailed Web Page

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity; Spasm

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior Disorders; Neurodevelopmental Disorders; Mental Disorders; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Maria T Acosta, M.D.

  National Human Genome Research Institute (NHGRI)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 18, 2002
• First Posted: September 19, 2002
• Study Start: February 8, 2000
• Primary Completion: January 30, 2019
• Study Completion: January 24, 2020
• Last Updated: December 24, 2024

Record last verified: 2024-12

Locations

US (2)